A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.» Read More
Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.
CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and AstraZeneca reach an agreement to launch a Crestor generic in 2016.
AstraZeneca settled a patent dispute with generic drug maker Watson Laboratories over its cholesterol drug Crestor, reports CNBC's Bertha Coombs.
One sector that is yet to be truly tapped in Africa is the brewing industry, according to research firm Bernstein Research, which believes it is probably the most attractive region for long-term profit growth for global brewers.
Sometimes, when a stock surges on an analyst upgrade, it's high time to make a bearish bet. That's exactly what one big options trader did on Walgreen.
After a difficult January, when shoppers first felt the effect of a payroll tax hike that lowered take-home pay by 2 percent, some retailers got a little relief in February from growing employment and a rising stock market.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
Moves by Indonesia's President Susilo Bambang Yudhoyono to put his finance minister in charge of the central bank is leading to concerns that he may be seeking someone more malleable to run the state coffers in the run up to next year's elections.
The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.
Mylan's aquisition of Agila is expected to double its business. Heather Bresch, Myland CEO, offers insight.
CNBC's Brian Shactman reports the Department of Justice is joining Floyd Landis in a lawsuit accusing Lance Armstrong using performance-enhancing drugs while being sponsored by the U.S. Postal Service. Armstrong says he did not cost the government money. Instead, he says the Postal Service actually benefitted to the tune of more than $100 million from its association with the disgraced cyclist.
Turberculosis is making a global comeback, including in the United States. Dr. William Schaffner of Vanderbilt University School of Medicine, discusses the concern surrounding the disease.
Retail sales barely rose in January as tax increases and higher gasoline prices restrained spending. Separately, import and export prices rose slightly less than expected in the month.
Washington State's liquor control board is seeking a marijuana consultant to help forge ahead regulation for its newly legalized substance. Steve Fox, director of government relations with the Marijuana Policy Project, offers insight.
Opko Health chairman and CEO Dr. Phillip Frost, offers insight on his company's acquisition of Cytochromas, its partnerships with companies like Bristol-Meyers Squibb, and where the company is headed this year.
Watson Pharmaceuticals has merged with Actavis, and will now trade on the NYSE under ticker symbol ACT. Its president & CEO Paul Bisaro, discusses the U.S. economy and the generic drug industry.
The world is gearing up for Lance Armstrong's big interview tonight with Oprah Winfrey. Robbie Vorhaus, founder & CEO of Vorhaus Communications, weighs in.